Apimeds Pharmaceuticals US APUS
NYSE APUS
$3.25 -0.25 (-7.14%)
As of: Oct 20, 2026 · 3:58 PM EDT

Apimeds Pharmaceuticals US (APUS) Operating Leases (2025 - 2026)

Updated

Apimeds Pharmaceuticals US (APUS) posted Operating Leases of $101,873 for Q2 2026.

Analysis

Apimeds Pharmaceuticals US (APUS) Operating Leases (2025 - 2026) Analysis & Trends

At the end of FY2025, Apimeds Pharmaceuticals US's Operating Leases came in at $129,454.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn
10 Apimeds Pharmaceuticals US 5.65 Mn -13.98 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 101,873.00
Dec 31, 2025 129,454.00
API Access

Apimeds Pharmaceuticals US Operating Leases API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=operating-leases&ticker=APUS&period=max&api_key=YOUR_API_KEY